Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (DE:V7B1)
FRANKFURT:V7B1
Holding DE:V7B1?
Track your performance easily
V7B1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€7.09 - €24.00
Previous Close€11.36
Volume0.00
Average Volume (3M)3.00K
Market Cap
€62.80M
Enterprise Value€20.81M
Total Cash (Recent Filing)$46.21M
Total Debt (Recent Filing)$919.00K
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Mar 07, 2024EPS Estimate
-€2.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding65,709,112
10 Day Avg. Volume0
30 Day Avg. Volume2,999
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.14
Price to Sales (P/S)308.79
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue136.00
Enterprise Value/Gross Profit136.00
Enterprise Value/Ebitda-0.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Assembly Biosciences News
PremiumCompany Announcements
Assembly Biosciences Executes Reverse Stock Split
PremiumCompany Announcements
Assembly Biosciences Announces 1-for-12 Reverse Stock Split
PremiumCompany Announcements
Assembly Biosciences Approves Reverse Split and Gilead Stock Issuance
V7B1 FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was €7.09 and its highest was €24.00 in the past 12 months.
What is Assembly Biosciences’s market cap?
Currently, no data Available
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Mar 07, 2024 which is 203 days ago.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Nov 08, 2023. The company reported -€3.004 earnings per share for the quarter, missing the consensus estimate of -€2.615 by -€0.389.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Overvalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -€2.61.
How many shares outstanding does Assembly Biosciences have?
Currently, no data Available
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -€3.004 in its last earnings report, missing expectations of -€2.615. Following the earnings report the stock price went down -14.243%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Among the largest hedge funds holding Assembly Biosciences’s share is Platinum Investment Management. It holds Assembly Biosciences’s shares valued at N/A.
---
Assembly Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $788.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.80%
12-Months-Change
Fundamentals
Return on Equity
-100.84%
Trailing 12-Months
Asset Growth
-57.51%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
---
V7B1 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
ANI Pharmaceuticals
―
Arrowhead Pharmaceuticals
―
Aslan Pharmaceuticals
―
Assembly Biosciences
―
AIM ImmunoTech
―
Best Analysts Covering V7B1
1 Year
1 Year Success Rate
1/26 ratings generated profit
1 Year Average Return
-44.22%
reiterated a buy rating a year ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 3.85% of your transactions generating a profit, with an average return of -44.22% per trade.
---